INDIA – AstraZeneca Pharma India Ltd. has appointed Dr. Sanjeev Panchal as Country President and Managing Director for a three-year term beginning January 1, 2023.
He succeeds Gagandeep Singh Bedi, who will be reappointed in a global position within the group, the pharmaceutical company informed in a statement.
With over 19 years of experience in the pharmaceutical industry, he will be taking forward the commitment of the organization in the country.
He has progressed through multiple positions at AstraZeneca in India, Indonesia, Asia Pacific, Singapore and the United Kingdom.
“Sanjeev is currently the Country President for AstraZeneca Malaysia, where he has been instrumental in transforming the business,” the company stated.
The science graduate (BSc) with Post Graduation and Doctorate in Business Administration (PhD) has been driving new launches, innovative patient-centric partnerships and Market Access strategies.
In a news release, AstraZeneca said Sanjeev led an inclusive and diverse team to achieve double-digit growth outpacing the market.
Furthermore, he has played a central role in supporting the Malaysian government in combating the COVID-19 pandemic.
The pharma giant highlighted that he backed AstraZeneca’s Covid-19 vaccine and long-acting monoclonal antibodies while leading the Corporate Affairs strategy and sustainability initiatives.
Upon being notified of his appointment, Panchal said: “I am delighted to return to India and take on the journey that Gagandeep Singh has established for the country.”
He further expressed his readiness to collaborate with the AstraZeneca India team to ensure they continue to push the boundaries of science to make health happen for people, society and planet.
“AstraZeneca’s bold ambition is to be pioneers in science and transform patient outcomes by delivering a robust pipeline of new medicines and leading in sustainability,” the science graduate outlined.
He emphasized that expansion, innovation, and patient-centric partnership are at the heart of how the group makes health happen, supported by the company’s diversity and driven by their shared goal.
Commenting on the appointment, Singh said: “I am very happy to see my fellow colleague and friend Sanjeev coming into this role and wish him all the best to capitalize on the opportunity ahead of us.”
He further said that with strong consistent growth across disease areas, they are poised to achieve leadership in existing portfolio and to explore more areas to be able to extend benefits to more patients.